TechnoDerma announced the appointment of key members of the Scientific Advisory Board, Professor Xiang Leihong, a dermatologist at Fudan University School of medicine, Dr. John Mao, a senior drug R & D expert in the San Francisco Bay area, Professor G
TDM-105795 is the Lead Small Molecule Drug in Topical Formulation
Established in 2014, Technoderma is a leader in the research and development of innovative drugs for skin indications. The success of this round of financing provides a strong support for the company to rapidly advance the preclinical research and
Chesson Labs is pleased to announce that LIQUICURE®--A New topical product to treat nail damage approved by the National Medical Products Administration (NMPA) is now available in China
TechnoDerma has built a number of dermatological disease pipelines through independent R&D and license-in. The company is gradually growing into a globally-positioned innovative drug research and development company specialized in dermatology. TechnoD
TechonoDerma is an innovation-oriented R&D biotech focusing on the development of novel small molecule drugs for dermatological conditions. Located in Jiaxing Xiuzhou Biopharmaceutical National Park, TechnoDerma has been designated as a leading enterprise by the Jiaxing Municipal Government of Zhejiang Province.
The company's current R&D pipeline includes candidate drugs for hair loss, atopic dermatitis, psoriasis, and systemic lupus erythematosus (SLE). TechnoDerma's first and the most advanced research and development program is the first-in-class small molecule drug candidate TDM-105795 for the treatment of androgenetic alopecia (AGA), which has been granted global intellectual property rights. In addition, TechnoDerma has several ongoing programs for the treatment of psoriasis and atopic dermatitis.
